eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2020
vol. 107
 
Share:
Share:
more
 
 
abstract:
Case report

Risankizumab as an effective therapeutic option in severe psoriasis unsuccessfully treated with therapies involving anti- TNF-α and anti-IL-17

Michał Adamczyk
1
,
Dorota Krasowska
1

1.
Department of Dermatology, Venereology, and Paediatric Dermatology, Medical University of Lublin, Poland
Dermatol Rev/Przegl Dermatol 2020, 107, 385-392
Online publish date: 2020/10/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Lack or loss of efficacy of biologic treatment in patients with severe plaque psoriasis is more and more often observed in clinical practice. A new group of drugs, which antagonize the p19 subunit of interleukin 23, is an interesting therapeutic option in this group of patients.

Objective
To show difficulties in choosing an effective biologic treatment in a patient with severe plaque psoriasis.

Case report
A 36-year-old man with severe psoriasis had been administered adalimumab and infliximab; however, in both cases loss of treatment efficacy was observed. Then, ixekizumab was administered to the patient. During a 16-week therapy, further exacerbation of psoriasis was observed – at the moment when the drug was discontinued PASI equalled 51, and BSA – 89%. The patient was started on risankizumab, and a complete remission of psoriasis was achieved in subsequent weeks of the treatment.

Conclusions
The case is being presented due to difficulties in choosing the right treatment, extreme exacerbation of psoriatic lesions, and a rarely observed complete inefficacy of anti-IL-17A biologic drug. Risankizumab proved to be an effective drug when other biologic drugs turned out to be ineffective.

keywords:

psoriasis, biologic treatment, anti-TNF drugs, anti-IL-17 drugs, anti-IL-23 drugs

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe